The Choice on Termination of Pregnancy Act 92 of 1996 embodies a laudable and liberal ideal, namely that the course of a woman’s life does not have to be determined by her reproductive capacity. Instead, she has the right to free, non-therapeutic termination of pregnancy in a safe environment, a right which exists up to the end of the second trimester. Dignity, equality, and security of the per...

objective: comparing sublingual and vaginal misoprostol in second trimester pregnancy termination. materials and methods: in this study 268 women at 12-24 weeks of gestation candidate for pregnancy termination were enrolled. women were randomly divided in two groups. the first group received 400 µg sublingual misoprostol and vaginal placebo and the second group received 400 µg vaginal misoprost...

There are two potential advantages of mid trimester diagnosis of fetal heart disease. Perinatal management in an environment where the appropriate expertise is available and prepared might result in improved outcomes after intervention in the newborn period in situations where this is required. Alternatively, prenatal diagnosis of congenital heart disease allows consideration of termination of ...

reproductive behavior of 1525 pregnant woman were studied in the time of termination of pregnancy in relation to maternal age, education, prenatal care and the number of previous pregnancies. the results show that the frequency of maternal attendance at the centers of prenatal care is significantly related to maternal education. and the total pregnancies per woman are inversely correlated with ...

Given the overall safety profile and increasing availability of medical pregnancy termination drugs, we asked: would the mifepristone-misoprostol regimen for medical termination at ≤10 weeks of gestation meet US Food and Drug Administration regulatory criteria for over-the-counter (OTC) approval, and if not, what are the present research gaps? We conducted a literature review of consumer behavi...